Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAT010 plus pembrolizumab in advanced solid tumors
ChiCTR2600121542Phase 2Not yet recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LAT010 and pembrolizumab in Nonhematologic neoplasms and solid tumor, sponsored by Shanxi Bethune Hospital. Primary endpoints: Treatment-emergent adverse events (TEAEs), Dose-limiting toxicities (DLTs) incidence and toxicity profile and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
LAT010pembrolizumab
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on ChiCTR2600121542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121542.